The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial.
Paul E. Goss
No relevant relationships to disclose
Carlos H. Barrios
Consultant or Advisory Role - Novartis
Arlene Chan
No relevant relationships to disclose
Dianne M. Finkelstein
Consultant or Advisory Role - Amgen
Hiroji Iwata
Consultant or Advisory Role - Daiichi Sankyo
Miguel Martin
Consultant or Advisory Role - Amgen; Roche
Ada Braun
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Beiying Ding
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Tapan Maniar
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
Robert E. Coleman
Consultant or Advisory Role - Bayer
Honoraria - Amgen; Bayer
Expert Testimony - Novartis